Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/jmv.25733 http://scihub22266oqcxt.onion/10.1002/jmv.25733 32108352!7228274!32108352     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Med+Virol 2020 ; 92 (6): 540-545 Nephropedia Template TP {{tp|p=32108352|t=2020. Clinical trial analysis of 2019-nCoV therapy registered in China |pdf=|usr=}}{{32108352}} gab.com Text Clinical trial analysis of 2019-nCoV therapy registered in China JO: J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32108352 #FOAvip So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China has the stronger capability to carry out clinical trials of new drugs in emergency period. Twit Text FOAVip Clinical trial analysis of 2019-nCoV therapy registered in China ????J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32108352 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32108352 #FOAvip English Wikipedia <ref>{{Cite pmid|32108352}}</ref> Clinical trial analysis of 2019-nCoV therapy registered in China #MMPMID32108352 Zhang Q; Wang Y; Qi C; Shen L; Li J J Med Virol 2020[Jun]; 92 (6): 540-545 PMID32108352show ga So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China has the stronger capability to carry out clinical trials of new drugs in emergency period. |*Disease Outbreaks[MESH] |Adenosine Monophosphate/analogs & derivatives/therapeutic use[MESH] |Alanine/analogs & derivatives/therapeutic use[MESH] |Amides/therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |Betacoronavirus/drug effects/genetics/pathogenicity[MESH] |COVID-19[MESH] |China/epidemiology[MESH] |Chloroquine/analogs & derivatives/therapeutic use[MESH] |Clinical Trials as Topic[MESH] |Coronavirus Infections/diagnosis/*drug therapy/*epidemiology/virology[MESH] |Disease Management[MESH] |Drugs, Chinese Herbal/*therapeutic use[MESH] |Humans[MESH] |Medicine, Chinese Traditional/methods[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/*drug therapy/*epidemiology/virology[MESH] |Practice Guidelines as Topic[MESH] |Pyrazines/therapeutic use[MESH]Clinical trial analysis of 2019-nCoV therapy registered in China (epmc).pdf DeepDyve Pubget Overpricing